Affiliation:
1. Department of Pharmacology, Toxicology and Therapeutics, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy,
V.M. Road, Vile Parle (W), Mumbai, India
Abstract
Abstract:
The PI3K/Akt/mTOR pathway modulates cell growth, proliferation, metabolism, and
movement. Moreover, significant studies have shown that the genes involved in this pathway are
frequently activated in human cancer. Observational and computational modeling of the PI3K/AKt/
mTOR pathway inhibitors has been explored in clinical trials. It has been observed that the effectiveness
and safety evidence from clinical studies and various inhibitors of this route have been given
FDA approval. In this review article, we focused on the processes behind the overactivation of
PI3K/Akt/mTOR signaling in cancer and provided an overview of PI3K/Akt/mTOR inhibitors as
either individual drugs or a combination of different doses of drugs for different types of cancer.
Furthermore, the review discusses the biological function and activation of the PI3K/AKt/mTOR
signaling and their role in the development of cancers. Additionally, we discussed the potential
challenges and corresponding prediction biomarkers of response and resistance for PI3K/Akt/m-
TOR inhibitor development. The article focuses on the most current breakthroughs in using the
PI3K/Akt/mTOR pathway to target certain molecules.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献